Oncotarget

Reviews:

mTOR: An attractive therapeutic target for osteosarcoma?

Liu Ding, Liu Congwei, Qing Bei, Yang Tao, Wang Ruiguo, Yu Heze, Dou Bo and Li Zhihong _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:50805-50813. https://doi.org/10.18632/oncotarget.9305

Metrics: PDF 2240 views  |   HTML 2926 views  |   ?  


Abstract

Liu Ding1,*, Liu Congwei1,*, Qing Bei2, Yang Tao3, Wang Ruiguo4, Yu Heze4, Dou Bo 4 and Li Zhihong1

1 Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

2 Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

3 Department of Otolaryngology, Head and Neck Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

4 Clinical Medicine for Eight-Year-Program, Xiangya School of Medicine, Central South University, Changsha, Hunan, China

* These authors have contributed equally to this work

Correspondence to:

Li Zhihong, email:

Keywords: osteosarcoma, mTOR, target, autophagy, apoptosis

Received: January 14, 2016 Accepted: May 05, 2016 Published: May 11, 2016

Abstract

Osteosarcoma (OS) is a common primary malignant bone tumor with high morbidity and mortality in children and young adults. How to improve poor prognosis of OS due to resistance to chemotherapy remains a challenge. Recently, growing findings show activation of mammalian target of rapamycin (mTOR), is associated with OS cell growth, proliferation, metastasis. Targeting mTOR may be a promising therapeutic approach for treating OS. This review summarizes the roles of mTOR pathway in OS and present research status of mTOR inhibitors in the context of OS. In addition, we have attempted to discuss how to design a better treatment project for OS by combining mTOR inhibitor with other drugs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9305